1. The compounds provided in this document are selective Western Sahara inhibitors for people with variation of epidemic growth factor (RCE) receptor, including TMLR, tmlrcs, LR, LRCS, their preparation, pharmaceutical components containing these substances and active therapeutic drugs. Claim 1: consists of formula (1),a. For arilo or heterosexual； B for arilo or heterosexual； C for heterosexual, R1 was selected from the tar group of 1-amino-2-c83331；(III) alcoxi c8321a8331832626；(IV) Ciano, V) halogen, VI) halogen hydrocarbon c833218331832626；（7） Halogen alcoxi c8321c8331832626 and VIII) water Xi； R2 were selected from the following groups, regardless of their composition:R830909，II - (C = O) - n (r83088)；R830909，（3） Halogens, iv-nh - (C = O) - c832131 asphalt； and (V) c832131 asphalt；R3: each substance is selected from the following groups: (1) amino group, 2) asphalt c8332183331；(III) alcoxi c8321a8331832626；(IV) Ciano, V) halogen, VI) halogen hydrocarbon c833218331832626；（7） Halogens alcoxi c8321c83318326 and (VIII) hydrogen； r83088 are selected from the following categories, regardless of their composition: (I) H and (II) c83218331 asphalt；R83099, selected from the following groups: (I) h, II) c8321883318c and (I II) - (C = O) - acquiro c83218832626；O r83088 and r83099 together with N form a different bicycle, in this case, the different bicycle can be replaced by r8310；R8310, each of which is selected from a group consisting of one - Oh, two - c8332183318c and three - (C = O) - asphalt c83216c；K is 0, 1 or 2； n is 0, 1, 2 or 3； m is 0, 1 or 2； P is 0 or 1； or is a pharmaceutically acceptable salt.La presente proporciona compuestos que son inhibidores alostéricos selectivos de mutantes de receptor del factor de crecimiento epidérmico (RFCE) que contienen TMLR, TMLRCS, LR, LRCS, su preparación, composiciones farmacéuticas que los contienen y su utilización como sustancias terapéuticas activas. Reivindicación 1: Compuesto de fórmula (1), en la que: A es arilo o h
